Skip to main content

Biosyent Inc(RX-X)
TSX Venture

Today's Change
Delayed Last Update

Closing Bell: Biosyent Inc up on Monday (RX)

Automated Summaries - The Globe and Mail - Mon Apr 8, 4:02PM CDT

Today in trading, Biosyent Inc shares closed at $8.65 after opening the day at $8.74. prices ranged from a low of $8.63 to a high of $8.75.

The price boosted 0.35 percent from the previous day's close of $8.62.

During the day across North America, the TSX Composite closed 0.96% at 22264.38, the S&P 500 closed 1.11% at 5204.34, the Dow Jones Industrial Average closed 0.80% at 38904.04 and the Nasdaq Composite closed 1.24% at 16248.52.

Biosyent Inc traded under RX on the Toronto Venture Exchange (TSX-V).

A total of 2,772 shares was traded during the last trading day, with total trades of 9. On average, Biosyent Inc has traded 4,429 shares over 5 days and 4,917 year-to-date.

The TSX-V overall saw 3,142 price advancers against 2,094 declines and 118 unchanged.

During the prior 52 weeks, RX.VN has traded as high as $9.26 (December 29,2023) and low as $7.03 (July 06,2023). Moreover, in the last 52 weeks, Biosyent Inc's shares have boosted 13.97%, while they have dipped -6.18% this year.

It announced a 0.04 dividend on February 07/24, with an February 28/24 ex-date and March 15/24 pay day.

Following today's trading, Biosyent Inc has a market capitalization of $100.13 million on a float of 11,616 shares outstanding. Its annual EPS is $0.53.

Biosyent Inc is a TSX Drug Specialty & Generic company headquartered in Mississauga, CAN.

Currently, Biosyent Inc has an average recommendation of "Moderate Buy" based on 1.00 analysts according to Zacks. From those 1 analysts, 1 have buy ratings.

AI at The Globe and Mail
This report is produced using automated technology that summarizes market data into articles for our readers. Ongoing project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities..

More from The Globe